A new era for glioma therapy - targeting mutant IDH

David A Reardon^{1

2}, Daniel P Cahill^{3

4}

Affiliations

¹ Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. david_reardon@dfci.harvard.edu.
² Department of Medicine, Harvard Medical School, Boston, MA, USA. david_reardon@dfci.harvard.edu.
³ Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA.
⁴ Department of Neurosurgery, Harvard Medical School, Boston, MA, USA.

Comment

David A Reardon et al. Nat Rev Clin Oncol. 2023 Nov.

. 2023 Nov;20(11):737-738.

doi: 10.1038/s41571-023-00804-8.

David A Reardon^{1

2}, Daniel P Cahill^{3

4}

¹ Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. david_reardon@dfci.harvard.edu.
² Department of Medicine, Harvard Medical School, Boston, MA, USA. david_reardon@dfci.harvard.edu.
³ Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA.
⁴ Department of Neurosurgery, Harvard Medical School, Boston, MA, USA.

No abstract available

Comment on

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF; INDIGO Trial Investigators. Mellinghoff IK, et al. N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272516 Free PMC article. Clinical Trial.

1. Mellinghoff, I. K. et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2304194 (2023). - DOI - PubMed
1. Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807–1812 (2008). - DOI - PubMed - PMC
1. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009). - DOI - PubMed - PMC
1. Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 (2009). - DOI - PubMed - PMC
1. Pirozzi, C. J. & Yan, H. The implications of IDH mutations for cancer development and therapy. Nat. Rev. Clin. Oncol. 18, 645–661 (2021). - DOI - PubMed